News & Updates

Advanced liver fibrosis a red flag for poor outcomes in T2D

18 Jul 2023

Among individuals with type 2 diabetes (T2D), the risk of poor outcomes such as heart failure and hospitalizations is high in the presence of advanced liver fibrosis, according to a study.

Advanced liver fibrosis a red flag for poor outcomes in T2D

18 Jul 2023

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

11 Jul 2023

Treatment with anticoagulants helps improve survival in patients with cirrhosis and portal vein thrombosis independently of recanalization, suggests a study. However, anticoagulation may increase the risk of nonportal hypertension-related bleeding.

Anticoagulation lowers mortality in patients with cirrhosis, portal vein thrombosis

11 Jul 2023

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023 by

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

NAFLD a risk factor for young-onset hypertension

09 Jun 2023

Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.

NAFLD a risk factor for young-onset hypertension

09 Jun 2023

Noninvasive fibrosis test for chronic liver diseases: Which tools, and how often?

02 Jun 2023 by

According to data presented at HKMF 2023, transient elastography (TE) is preferred for noninvasive assessment of fibrosis for patients with chronic liver diseases (CLDs) in Hong Kong. Liver stiffness measurement (LSM) using noninvasive tests (NITs) can be repeated annually to monitor disease progression in patients with compensated advanced CLDs (cACLDs).

Noninvasive fibrosis test for chronic liver diseases: Which tools, and how often?

02 Jun 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).